Post-Treatment Weight Rebound in Patients Using Anti-Obesity Medications
A new meta-analysis reveals that weight loss achieved through anti-obesity medications often diminishes within weeks after stopping treatment, highlighting the need for sustained weight management strategies.
Recent research indicates that individuals prescribed anti-obesity medications may experience significant weight regain after discontinuing their treatment. A comprehensive meta-analysis, published in BMC Medicine, analyzed data from 11 international studies involving 1,574 participants on medication and 893 control subjects. The findings reveal that while these medications effectively promote weight loss during use, the effects diminish—often sharply—within weeks after cessation.
The study categorized the medications into several types, including GLP-1 receptor agonists (such as semaglutide), dual GLP-1 and dual receptor agonists, orlistat, phentermine-topiramate, and naltrexone-bupropion. The analysis controlled for various factors such as the presence of diabetes and lifestyle changes like diet and exercise.
Results showed that weight loss peaks during treatment but begins to reverse approximately eight weeks after stopping medication. Weight regain continues over an average of 20 weeks before reaching a plateau. The extent of weight regain varies depending on several factors, including the specific medication used and adherence to lifestyle modifications. For instance, individuals who completed a 36-week tirzepatide regimen regained nearly half of the weight lost after switching to a placebo.
The researchers highlight that these findings do not compare medication effects with lifestyle interventions or surgical options like bariatric surgery. Nonetheless, the evidence underscores the challenge of maintaining weight loss after pharmacological treatment ends. The study emphasizes ongoing weight management strategies and regulatory considerations for long-term treatment plans.
In conclusion, anti-obesity drugs are effective for short-term weight reduction, but many patients tend to experience weight rebound after stopping treatment. This underscores the importance of continued support and the potential need for adjunct therapies or lifestyle modifications to sustain weight loss over time.
Source: https://medicalxpress.com/news/2025-07-anti-obesity-medications-weight-rebound.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
FDA Approves Innovative Eye Implant to Combat Vision Loss in Rare Retina Disease
The FDA has approved ENCELTO, a groundbreaking eye implant that slows vision loss in patients with macular telangiectasia type 2, offering hope through advanced neuroprotective therapy.
US Measles Outbreak Surpasses 2019 Numbers as Missouri Reports New Cases
The U.S. faces its worst measles outbreak since 1991 with over 1,288 cases reported in 2025. Key states including Texas, Missouri, and others are experiencing new transmission, emphasizing the critical need for vaccination to prevent further spread.
Young Woman Overcomes 40-Pound Tumor in Life-Saving Surgery and Celebrates Wedding
Adriana Pulido's extraordinary journey from life-threatening tumor to walking down the aisle showcases advances in complex tumor surgery and remarkable resilience. Her story underscores the importance of specialized medical care in overcoming severe health challenges.
Study Shows Cost-Effective Benefits of Intensive Blood Pressure Targets
Research shows that intensive blood pressure control below 120 mm Hg is a cost-effective strategy to reduce cardiovascular events, despite potential risks and higher healthcare costs. Learn about the latest findings on blood pressure management.